Janus Kinase Inhibitor

Ritlecitinib and brepocitinib induction therapies more effectively reduced total Mayo Score compared with placebo in patients with moderate to severe ulcerative colitis, according to data in Clinical Gastroenterology and Hepatology.

Healio Rheumatology’s stories “stifling the negativity” between DOs and MDs, and documenting the health care industry’s lack of response to “tectonic shifts” in paid family leave, were by far its most popular among readers in 2022.

NEW ORLEANS — In this video, Aaron T. Gerds, MD, MS, assistant professor at the Cleveland Clinic Taussig Cancer Institute, discusses updated results from the Momentum phase 3 study presented at the ASH Annual Meeting and Exposition.

Understanding the mechanism of action by which psoriatic arthritis treatment works and taking a patient’s lifestyle into account can benefit clinicians treating patients with the condition, said Philip J. Mease, MD, of the Swedish Medical Center in Seattle and the University of Washington.

A speaker at the American College of Rheumatology’s annual conference reviewed data on the association between Janus kinase inhibitors and elevated risks for cardiovascular events and malignancy.

PHILADELPHIA — Making sense of real-world data and black-box warnings associated with Janus kinase inhibitors can be challenging for rheumatologists hoping to prescribe these medications, according to a presenter at ACR Convergence 2022.